NovaDel Pharma (NVD) to Enter into Exclusive License and Distribution Agreement with ECR Pharma for ZolpiMist
NovaDel Pharma Inc. (AMEX: NVD) today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist in the United States and Canada.
Under the terms of the agreement, ECR will pay NovaDel $3 million upon the execution of the agreement. ECR will assume responsibility for manufacturing and marketing the product in the United States and Canada. In addition, ECR will pay royalties of up to 15% on net sales of ZolpiMist as well as an additional milestone payment if sales reach a specified level.
Steven B. Ratoff, Chairman and Interim CEO said, "This is an important milestone for our company as it recognizes the opportunity of the use of our NovaMist oral spray technology in what we believe to be an important and sizable clinical application. We believe that Hi-Tech has the ability to build a solid position for ZolpiMist in the market for prescription sleep aids."
ZolpiMist is an oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.
Under the terms of the agreement, ECR will pay NovaDel $3 million upon the execution of the agreement. ECR will assume responsibility for manufacturing and marketing the product in the United States and Canada. In addition, ECR will pay royalties of up to 15% on net sales of ZolpiMist as well as an additional milestone payment if sales reach a specified level.
Steven B. Ratoff, Chairman and Interim CEO said, "This is an important milestone for our company as it recognizes the opportunity of the use of our NovaMist oral spray technology in what we believe to be an important and sizable clinical application. We believe that Hi-Tech has the ability to build a solid position for ZolpiMist in the market for prescription sleep aids."
ZolpiMist is an oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Cytokinetics (CYTK) Opens Second Cohort for ATOMIC-AHF Phase IIb
- Mylan (MYL) Unit Launches Generic Viramune Tabs
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
